Skip to main
RPTX
RPTX logo

Repare Therapeutics (RPTX) Stock Forecast & Price Target

Repare Therapeutics (RPTX) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 67%
Buy 17%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Repare Therapeutics Inc. has demonstrated promising advancements in precision oncology, particularly with the favorable tolerability of its camonsertib + lunresertib combination therapy, which has shown a significant reduction in anemia rates through individualized schedule optimization. The company’s ACR-2316, a dual Wee1/Myt1 inhibitor, has outperformed competitor therapies in reducing tumor volume across various models, highlighting its strong potential in clinical applications. Furthermore, the incorporation of risk-adjusted revenue projections for the promising RP-3467 therapy, alongside positive preclinical outcomes, underpins a positive outlook on the company's future financial performance.

Bears say

Repare Therapeutics Inc. faces significant risks that contribute to a negative outlook on its stock, including the potential for negative data from key proof-of-concept trials, which could hinder the advancement of their drug candidates into later-stage trials. Additionally, the company may encounter challenges in obtaining regulatory approval for its agents, along with partnership risks that could hinder strategic collaborations essential for development. Compounding these issues are concerns regarding the slower-than-anticipated market uptake for its therapies due to pricing challenges and competitive pressures, alongside the risk of long-term dilution for existing shareholders.

Repare Therapeutics (RPTX) has been analyzed by 6 analysts, with a consensus rating of Buy. 67% of analysts recommend a Strong Buy, 17% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Repare Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Repare Therapeutics (RPTX) Forecast

Analysts have given Repare Therapeutics (RPTX) a Buy based on their latest research and market trends.

According to 6 analysts, Repare Therapeutics (RPTX) has a Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Repare Therapeutics (RPTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.